Ferric citrate hydrate improves transferrin saturation in patients with low levels of transferrin saturation undergoing hemodialysis
Although it has been established that patients with chronic kidney disease and iron deficiency, as indicated by a transferrin saturation of < 20%, are at increased risk of all-cause mortality and cardiovascular events, the optimal management of such patients has not yet been determined. In this p...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2395449 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849763428952965120 |
|---|---|
| author | Keitaro Yokoyama Ryo Inoue Kyoko Ito Yuko Mitobe |
| author_facet | Keitaro Yokoyama Ryo Inoue Kyoko Ito Yuko Mitobe |
| author_sort | Keitaro Yokoyama |
| collection | DOAJ |
| description | Although it has been established that patients with chronic kidney disease and iron deficiency, as indicated by a transferrin saturation of < 20%, are at increased risk of all-cause mortality and cardiovascular events, the optimal management of such patients has not yet been determined. In this post hoc subgroup analysis, we aimed to clarify the effect of ferric citrate hydrate on transferrin saturation in patients with chronic kidney disease and low transferrin saturation (< 20%) undergoing hemodialysis. To accomplish this, we extracted the relevant data on a subset of patients drawn from two previous studies: the ASTRIO study (A Study examining the contribution to Renal anemia treatment with ferric citrate hydrate, Iron-based Oral phosphate binder, UMIN000019176) and a post-marketing surveillance study. The subset of patients used for the present study were those with baseline transferrin saturation < 20%. We found that administration of ferric citrate hydrate increased transferrin saturation and maintained transferrin saturation at approximately 30%. However, because we did not have access to data on all-cause mortality or cardiovascular events, we could not ascertain whether the frequency of these outcomes was reduced in parallel with improvements in transferrin saturation. Further large studies are required. |
| format | Article |
| id | doaj-art-acf5484945b4468bb8e37c70a22696fb |
| institution | DOAJ |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-acf5484945b4468bb8e37c70a22696fb2025-08-20T03:05:25ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492024-12-0146210.1080/0886022X.2024.2395449Ferric citrate hydrate improves transferrin saturation in patients with low levels of transferrin saturation undergoing hemodialysisKeitaro Yokoyama0Ryo Inoue1Kyoko Ito2Yuko Mitobe3Department of Health Science, The Graduate School, Jikei University School of Medicine, Tokyo, JapanMedical Affairs Department, Torii Pharmaceutical, Tokyo, JapanMedical Affairs Department, Torii Pharmaceutical, Tokyo, JapanMedical Affairs Department, Torii Pharmaceutical, Tokyo, JapanAlthough it has been established that patients with chronic kidney disease and iron deficiency, as indicated by a transferrin saturation of < 20%, are at increased risk of all-cause mortality and cardiovascular events, the optimal management of such patients has not yet been determined. In this post hoc subgroup analysis, we aimed to clarify the effect of ferric citrate hydrate on transferrin saturation in patients with chronic kidney disease and low transferrin saturation (< 20%) undergoing hemodialysis. To accomplish this, we extracted the relevant data on a subset of patients drawn from two previous studies: the ASTRIO study (A Study examining the contribution to Renal anemia treatment with ferric citrate hydrate, Iron-based Oral phosphate binder, UMIN000019176) and a post-marketing surveillance study. The subset of patients used for the present study were those with baseline transferrin saturation < 20%. We found that administration of ferric citrate hydrate increased transferrin saturation and maintained transferrin saturation at approximately 30%. However, because we did not have access to data on all-cause mortality or cardiovascular events, we could not ascertain whether the frequency of these outcomes was reduced in parallel with improvements in transferrin saturation. Further large studies are required.https://www.tandfonline.com/doi/10.1080/0886022X.2024.2395449chronic kidney diseasedialysisferric citrate hydrateiron deficiencytransferrin saturation |
| spellingShingle | Keitaro Yokoyama Ryo Inoue Kyoko Ito Yuko Mitobe Ferric citrate hydrate improves transferrin saturation in patients with low levels of transferrin saturation undergoing hemodialysis Renal Failure chronic kidney disease dialysis ferric citrate hydrate iron deficiency transferrin saturation |
| title | Ferric citrate hydrate improves transferrin saturation in patients with low levels of transferrin saturation undergoing hemodialysis |
| title_full | Ferric citrate hydrate improves transferrin saturation in patients with low levels of transferrin saturation undergoing hemodialysis |
| title_fullStr | Ferric citrate hydrate improves transferrin saturation in patients with low levels of transferrin saturation undergoing hemodialysis |
| title_full_unstemmed | Ferric citrate hydrate improves transferrin saturation in patients with low levels of transferrin saturation undergoing hemodialysis |
| title_short | Ferric citrate hydrate improves transferrin saturation in patients with low levels of transferrin saturation undergoing hemodialysis |
| title_sort | ferric citrate hydrate improves transferrin saturation in patients with low levels of transferrin saturation undergoing hemodialysis |
| topic | chronic kidney disease dialysis ferric citrate hydrate iron deficiency transferrin saturation |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2395449 |
| work_keys_str_mv | AT keitaroyokoyama ferriccitratehydrateimprovestransferrinsaturationinpatientswithlowlevelsoftransferrinsaturationundergoinghemodialysis AT ryoinoue ferriccitratehydrateimprovestransferrinsaturationinpatientswithlowlevelsoftransferrinsaturationundergoinghemodialysis AT kyokoito ferriccitratehydrateimprovestransferrinsaturationinpatientswithlowlevelsoftransferrinsaturationundergoinghemodialysis AT yukomitobe ferriccitratehydrateimprovestransferrinsaturationinpatientswithlowlevelsoftransferrinsaturationundergoinghemodialysis |